C4 Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

C4 Therapeutics

28/07/2025 13:56

C4 Therapeutics Inc CCCC.OQ CCCC.O is expected to  show a fall in quarterly revenue when it reports  results on July 30 (estimated) for the period ending June 30 2025

The Watertown Massachusetts-based  company is expected to report a 45.4% decrease in revenue to $6.55 million from $12.01 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for C4 Therapeutics Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for C4 Therapeutics Inc is $7.00, about 67.7% above its last closing price of $2.26

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.48
-0.45
-0.37
Beat
17.8
Dec. 31 2025
-0.47
-0.48
-0.49
Missed
-2.6
Sep. 30 2024
-0.36
-0.38
-0.35
Beat
7.9​
Jun. 30 2024
-0.37
-0.37
-0.26
Beat
30
​​Mar. 31 2024
-0.36
-0.35
-0.41
Missed
-16.7
Dec. 31 2023
-0.64
-0.68
-0.70
Missed
-2.6​
Sep. 30 2023
-0.67
-0.66
-0.52
Beat
21.2
Jun. 30 2023
-0.69
-0.69
-0.73
Missed
-6.1

This summary was machine generated July 28 at 12:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)